Utama › Limfoma Burkitt › Oklahoma › Oklahoma City
Kajian klinikal Limfoma Burkitt di Oklahoma City, OK
7 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi dalam dan sekitar Oklahoma City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Mengambil pesertaFasa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mengambil pesertaFasa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Mengambil pesertaFasa 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Kajian Limfoma Burkitt di bandar lain
- Houston, TX21 kajian
- Philadelphia, PA16 kajian
- Milwaukee, WI16 kajian
- Chicago, IL15 kajian
- Cincinnati, OH13 kajian
- New York City, NY13 kajian
- Atlanta, GA12 kajian
- Aurora, CO11 kajian
- Seattle, WA11 kajian
- Durham, NC10 kajian
- Boston, MA10 kajian
- Kansas City, MO10 kajian
Kajian lain di Oklahoma City
- Kanser Paru-paru Bukan Sel Kecil28 kajian
- Kanser Ovari28 kajian
- Kanser Endometrium25 kajian
- Kanser Kolorektal22 kajian
- Kanser Prostat21 kajian
- Kanser Paru-paru19 kajian
- Kanser Payudara17 kajian
- Kanser Metastatik16 kajian
- Kanser (semua jenis)14 kajian
- Leukemia Mieloid Akut14 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher13 kajian
- Kanser Pundi Kencing11 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.